Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.76 – $3.95
0% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.2M | $45.3M | $105.5M | $176.8M | $1.26B | $2.24B | $1.95B | $1.49B |
| Cost of revenue | $584.0K | $5.8M | $14.1M | $13.2M | $255.0M | $408.9M | $939.0M | $913.0M |
| Gross profit | $12.6M | $39.6M | $91.4M | $163.6M | $1.00B | $1.83B | $1.01B | $580.4M |
| Gross margin | 95.6% | 87.3% | 86.6% | 92.5% | 79.7% | 81.7% | 51.8% | 38.9% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $354.3M | $119.1M |
| Operating income | −$23.0K | $372.0K | −$3.8M | −$66.1M | −$236.9M | −$996.9M | −$289.1M | −$251.5M |
| EBITDA | $696.0K | $3.7M | $5.8M | −$39.5M | $31.8M | $322.3M | −$111.1M | −$34.8M |
| Net income | $155.0K | $1.2M | $581.0K | −$61.9M | −$227.6M | −$832.9M | −$5.5M | −$1.09B |
| Net margin | 1.2% | 2.6% | 0.6% | -35.0% | -18.1% | -37.2% | -0.3% | -72.7% |
| EPS (diluted) | -0.03 | 0.04 | 0.02 | -1.47 | -3.71 | -12.45 | -0.01 | -15.40 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.6B | $-2.88 | $-2.94–$-2.84 | 1 |
| 2027 | $1.7B | $-1.59 | $-1.62–$-1.57 | 1 |
| 2028 | $1.8B | $-0.70 | $-0.71–$-0.69 | 1 |
Forward consensus · source: Financial Modeling Prep
BICO GROUP AB B
No one on the platform currently holds CLLKF.
No tracked institution reports a position in CLLKF as of their last filing.
No one on the platform has traded CLLKF yet.
| $135M |
| — |
| NDTPNDT Pharmaceuticals Inc. | $0.35 | -26.16% | $56M | — |
| NGENFNervGen Pharma Corp. | $3.95 | -2.47% | $313M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× sales vs its 0.2× historical median P/S.
Fair value ≈ $7.94 · price $1.76 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.